{"id":"florbetapir-f-18-18f-av-45","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Florbetapir F-18 is a fluorine-18 labeled tracer that crosses the blood-brain barrier and selectively binds to amyloid-beta aggregates, the hallmark pathological feature of Alzheimer's disease. When administered intravenously, it accumulates in brain regions with amyloid pathology and emits positrons that are detected by PET imaging, allowing visualization and quantification of amyloid burden. This enables early detection of amyloid pathology in patients with cognitive impairment or at risk for Alzheimer's disease.","oneSentence":"Florbetapir F-18 is a positron emission tomography (PET) imaging agent that binds to amyloid-beta plaques in the brain to detect Alzheimer's disease pathology.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:46:35.748Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Detection of amyloid-beta pathology in patients with cognitive impairment or suspected Alzheimer's disease"}]},"trialDetails":[{"nctId":"NCT05617014","phase":"","title":"Alzheimer's Disease Neuroimaging Initiative 4","status":"ENROLLING_BY_INVITATION","sponsor":"University of Southern California","startDate":"2023-06-09","conditions":"Mild Cognitive Impairment, Alzheimer Disease, Dementia","enrollment":1500},{"nctId":"NCT03019029","phase":"PHASE1, PHASE2","title":"Diagnostic Utility of F-18 Florbetapir PET/MR in Peripheral Nerve Amyloidosis","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2017-03-13","conditions":"Amyloidosis","enrollment":8},{"nctId":"NCT03860857","phase":"PHASE3","title":"Biomarker Exploration in Aging, Cognition and Neurodegeneration","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2018-05-01","conditions":"Alzheimer Disease, Cognitive Impairment, Cognitive Decline","enrollment":300},{"nctId":"NCT01683825","phase":"PHASE4","title":"Imaging Cardiac Amyloidosis: A Pilot Study Using F-18 Florbetapir Positron Emission Tomography","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2013-03-23","conditions":"Cardiac Amyloidosis","enrollment":23},{"nctId":"NCT02951598","phase":"","title":"A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2016-10-29","conditions":"Alzheimer Disease, Mild Cognitive Impairment","enrollment":1400},{"nctId":"NCT06600880","phase":"PHASE1","title":"Neuronavigation-guided FUS-induced BBB Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau","status":"NOT_YET_RECRUITING","sponsor":"Columbia University","startDate":"2026-08","conditions":"Alzheimer Disease, Early Onset","enrollment":6},{"nctId":"NCT01606488","phase":"PHASE4","title":"Effects of Brain Beta-Amyloid on Postoperative Cognition","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2012-05","conditions":"Postoperative Cognitive Dysfunction","enrollment":66},{"nctId":"NCT01447719","phase":"PHASE3","title":"Autopsy Follow-up of Subjects Previously Imaged With Florbetapir F 18 (18F-AV-45) PET in Trial 18F-AV-45-A07","status":"COMPLETED","sponsor":"Avid Radiopharmaceuticals","startDate":"2010-03","conditions":"Alzheimer's Disease","enrollment":110},{"nctId":"NCT05164536","phase":"PHASE1","title":"Plasma P-tau2017 and Quantitative Amyloid PET Imaging","status":"COMPLETED","sponsor":"Invicro","startDate":"2021-08-27","conditions":"Alzheimer Disease","enrollment":140},{"nctId":"NCT05806697","phase":"NA","title":"Investigation of AlzHeimer's Predictors in Subjective Memory Complainers - Extension Study","status":"RECRUITING","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2023-04-14","conditions":"Alzheimer Disease, Memory Complaint, Memory Disorders","enrollment":240},{"nctId":"NCT04390009","phase":"EARLY_PHASE1","title":"Entire-body PET Scans for Multiple Sclerosis","status":"RECRUITING","sponsor":"Brain Health Alliance","startDate":"2024-09-30","conditions":"Multiple Sclerosis","enrollment":20},{"nctId":"NCT01231971","phase":"","title":"Alzheimer's Disease Neuroimaging Initiative 2","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2011-02-14","conditions":"Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD), Significant Memory Concern (SMC)","enrollment":1182},{"nctId":"NCT04726527","phase":"","title":"Clinical Evaluation of Florbetapir in Primary Progressive Aphasia","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2012-03-15","conditions":"Primary Progressive Aphasia, Alzheimer Disease, Dementia","enrollment":48},{"nctId":"NCT04118764","phase":"NA","title":"Non-invasive Blood-brain Barrier Opening in Alzheimer's Disease Patients Using Focused Ultrasound","status":"COMPLETED","sponsor":"Columbia University","startDate":"2020-08-06","conditions":"Alzheimer Disease","enrollment":6},{"nctId":"NCT05820191","phase":"PHASE2","title":"B-amyloid as a Marker for GBM Bioimaging","status":"NOT_YET_RECRUITING","sponsor":"Universidad Central del Caribe","startDate":"2024-07","conditions":"Glioblastoma","enrollment":3},{"nctId":"NCT03019536","phase":"PHASE1","title":"A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-01-31","conditions":"Alzheimer Disease","enrollment":22},{"nctId":"NCT03333551","phase":"PHASE4","title":"Cardiac Uptake of 18F Florbetapir in Patients Undergoing Chemotherapy","status":"TERMINATED","sponsor":"Medical College of Wisconsin","startDate":"2020-10-01","conditions":"Cardiac Amyloidosis","enrollment":3},{"nctId":"NCT02062099","phase":"PHASE1","title":"PET Imaging of the Translocator Proteine Ligands (TSPO) With [18 F] DPA-714 Biomarker of NeuroInflammation in Cognitive Decline (NIDECO)","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2014-01","conditions":"Memory Complaint, Mild Cognitive Impairment, Alzheimer Disease","enrollment":25},{"nctId":"NCT01565382","phase":"PHASE3","title":"Evaluation of Inter-reader Reliability Using Images From Subjects With Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI)","status":"COMPLETED","sponsor":"Avid Radiopharmaceuticals","startDate":"2011-02","conditions":"Alzheimer's Disease","enrollment":40},{"nctId":"NCT01767493","phase":"PHASE4","title":"Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients","status":"COMPLETED","sponsor":"Institute for Neurodegenerative Disorders","startDate":"2012-11","conditions":"Multiple Sclerosis","enrollment":19},{"nctId":"NCT03040427","phase":"PHASE4","title":"The Role of F-18 Florbetapir in the Early Detection of Cardiac Amyloidosis","status":"TERMINATED","sponsor":"The Cleveland Clinic","startDate":"2017-01","conditions":"Cardiac Amyloidosis","enrollment":12},{"nctId":"NCT03902548","phase":"PHASE1","title":"Initial Investigation of [18F]P16-129 in Alzheimer's Disease Patients and Healthy Volunteers","status":"COMPLETED","sponsor":"Five Eleven Pharma, Inc.","startDate":"2018-02-21","conditions":"Alzheimer Disease","enrollment":14},{"nctId":"NCT02494531","phase":"NA","title":"Illiteracy and Vulnerability to Alzheimer's Disease: Evaluation of Amyloid Pathology by PET Imaging","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-12-12","conditions":"Alzheimer Disease","enrollment":45},{"nctId":"NCT04474405","phase":"EARLY_PHASE1","title":"Exploratory Evaluation of Flortaucipir Injection in Healthy Volunteers and Cognitively Impaired Subjects","status":"COMPLETED","sponsor":"Avid Radiopharmaceuticals","startDate":"2013-08-16","conditions":"Alzheimer Disease","enrollment":36},{"nctId":"NCT02016560","phase":"PHASE2, PHASE3","title":"Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects","status":"COMPLETED","sponsor":"Avid Radiopharmaceuticals","startDate":"2013-12","conditions":"Alzheimer's Disease","enrollment":383},{"nctId":"NCT02079766","phase":"PHASE2","title":"18F-AV-1451 and Florbetapir F 18 PET (Positron Emission Tomography) Imaging in Subjects at Risk for Chronic Traumatic Encephalopathy","status":"COMPLETED","sponsor":"Avid Radiopharmaceuticals","startDate":"2014-06","conditions":"Chronic Traumatic Encephalopathy","enrollment":41},{"nctId":"NCT02051764","phase":"PHASE2","title":"Imaging Characteristics of a Follow-up 18F-AV-1451 Scan","status":"TERMINATED","sponsor":"Avid Radiopharmaceuticals","startDate":"2014-05","conditions":"Alzheimer's Disease","enrollment":44},{"nctId":"NCT02759887","phase":"NA","title":"Relationship Between Down Syndrome (DS) and Alzheimer's Disease (AD)","status":"COMPLETED","sponsor":"St. Joseph's Hospital and Medical Center, Phoenix","startDate":"2016-11","conditions":"Down Syndrome, Alzheimer's Dementia","enrollment":19},{"nctId":"NCT02266563","phase":"","title":"Amyloid and Tauopathy PET Imaging in Acute and Chronic Traumatic Brain Injury","status":"COMPLETED","sponsor":"Samuel Gandy","startDate":"2015-01","conditions":"Traumatic Brain Injury, Chronic Traumatic Encephalopathy, Mild Cognitive Impairment","enrollment":46},{"nctId":"NCT01834716","phase":"NA","title":"Exercise in Asymptomatic Pre-Alzheimer's Disease Pilot Study","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2013-04","conditions":"Alzheimer's Disease Prevention","enrollment":16},{"nctId":"NCT02918539","phase":"","title":"Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials","status":"COMPLETED","sponsor":"Avid Radiopharmaceuticals","startDate":"2016-10","conditions":"Alzheimer Disease, Cognition Disorders","enrollment":317},{"nctId":"NCT01619709","phase":"NA","title":"Amyloid Imaging and Cognitive Impairment After Intracerebral Hemorrhage","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2012-01","conditions":"Intracerebral Hemorrhage","enrollment":70},{"nctId":"NCT01518374","phase":"PHASE2","title":"Clinical Evaluation of Florbetapir F 18 (18F-AV-45)","status":"COMPLETED","sponsor":"Avid Radiopharmaceuticals","startDate":"2009-12","conditions":"Alzheimer Disease, Mild Cognitive Impairment, Neurodegenerative Diseases","enrollment":1768},{"nctId":"NCT01459016","phase":"PHASE1","title":"A Non-drug Methods Study in Participants With Alzheimer's Disease","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-12","conditions":"Alzheimer's Disease","enrollment":56},{"nctId":"NCT02191267","phase":"PHASE2","title":"Tau Imaging of Chronic Traumatic Encephalopathy","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2015-01","conditions":"Chronic Traumatic Encephalopathy","enrollment":30},{"nctId":"NCT01746706","phase":"NA","title":"Can the Assessment of the Subhippocampal Region Contribute to the Detection of Early Diagnosis of Alzheimer's Disease? A Validation Study Using PET With Florbetapir (AV-45).","status":"UNKNOWN","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2011-10","conditions":"Alzheimer's Disease","enrollment":80},{"nctId":"NCT02667496","phase":"PHASE2","title":"Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease","status":"WITHDRAWN","sponsor":"Sanofi","startDate":"2016-11","conditions":"Dementia Alzheimer's Type","enrollment":""},{"nctId":"NCT02120664","phase":"PHASE1","title":"Florbetapir Calibration to the Centiloid Scale","status":"COMPLETED","sponsor":"Avid Radiopharmaceuticals","startDate":"2014-04","conditions":"Alzheimer's Disease","enrollment":35},{"nctId":"NCT02370524","phase":"PHASE1","title":"Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease","status":"COMPLETED","sponsor":"Molecular NeuroImaging","startDate":"2015-01","conditions":"Alzheimer's Disease (AD)","enrollment":16},{"nctId":"NCT02103894","phase":"PHASE1","title":"Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects","status":"COMPLETED","sponsor":"Molecular NeuroImaging","startDate":"2014-02","conditions":"Alzheimer's Disease (AD), Parkinson's Disease (PD), Chronic Traumatic Encephalopathy (CTE)","enrollment":16},{"nctId":"NCT01703702","phase":"PHASE4","title":"Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline","status":"COMPLETED","sponsor":"Avid Radiopharmaceuticals","startDate":"2012-10","conditions":"Alzheimer's Disease","enrollment":641},{"nctId":"NCT02039024","phase":"PHASE2","title":"Imaging Non-motor Symptoms of Parkinson's Disease by Novel 18F-DTBZ and Florbetapir F-18 PET","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2012-03","conditions":"Parkinson's Disease","enrollment":18},{"nctId":"NCT02051790","phase":"PHASE4","title":"Evaluation of Reader Training Processes","status":"COMPLETED","sponsor":"Avid Radiopharmaceuticals","startDate":"2014-03","conditions":"Alzheimer's Disease","enrollment":241},{"nctId":"NCT02107599","phase":"PHASE4","title":"The Feasibility of Florbetapir Quantitation in Europe","status":"COMPLETED","sponsor":"Avid Radiopharmaceuticals","startDate":"2014-03","conditions":"Alzheimer's Disease","enrollment":96},{"nctId":"NCT01946243","phase":"PHASE4","title":"The Feasibility of Florbetapir Quantitation","status":"COMPLETED","sponsor":"Avid Radiopharmaceuticals","startDate":"2013-08","conditions":"Alzheimers Disease","enrollment":96},{"nctId":"NCT02029547","phase":"NA","title":"Evaluation of Electronic Florbetapir (18F) Interpretation Training in Japanese Physicians","status":"WITHDRAWN","sponsor":"Avid Radiopharmaceuticals","startDate":"2014-10","conditions":"Alzheimer's Disease","enrollment":""},{"nctId":"NCT01890343","phase":"PHASE2","title":"Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls.","status":"COMPLETED","sponsor":"Avid Radiopharmaceuticals","startDate":"2009-09","conditions":"Alzheimer's Disease, Frontotemporal Dementia","enrollment":34},{"nctId":"NCT01660815","phase":"PHASE1","title":"A Study of Florbetapir (18F) in Japanese Healthy Volunteers","status":"COMPLETED","sponsor":"Avid Radiopharmaceuticals","startDate":"2012-08","conditions":"Alzheimer's Disease","enrollment":7},{"nctId":"NCT01662882","phase":"PHASE2, PHASE3","title":"A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)","status":"COMPLETED","sponsor":"Avid Radiopharmaceuticals","startDate":"2012-10","conditions":"Alzheimer's Disease, Mild Cognitive Impairment","enrollment":48},{"nctId":"NCT01400425","phase":"PHASE3","title":"Potential of Florbetapir F 18 PET to Inform Clinical Diagnosis and Management of Patients With Progressive Cognitive Decline","status":"COMPLETED","sponsor":"Avid Radiopharmaceuticals","startDate":"2011-07","conditions":"Progressive Cognitive Decline","enrollment":239},{"nctId":"NCT00857506","phase":"PHASE2","title":"Observational Study of Cognitive Outcomes for Subjects Who Have Had Prior PET Amyloid Imaging With Florbetapir F 18 (18F-AV-45)","status":"COMPLETED","sponsor":"Avid Radiopharmaceuticals","startDate":"2009-01","conditions":"Alzheimer's Disease, Mild Cognitive Impairment","enrollment":152},{"nctId":"NCT00857532","phase":"PHASE2","title":"Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients","status":"COMPLETED","sponsor":"Avid Radiopharmaceuticals","startDate":"2009-01","conditions":"Parkinson's Disease","enrollment":31},{"nctId":"NCT01503944","phase":"PHASE1, PHASE2","title":"A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET)","status":"COMPLETED","sponsor":"Avid Radiopharmaceuticals","startDate":"2010-03","conditions":"Dementia With Lewy Bodies, Alzheimer's Disease, Parkinson's Disease","enrollment":30},{"nctId":"NCT00855868","phase":"PHASE2","title":"Ability Of ([18F]-AV-45) PET Scan to Distinguish Alzheimer's Disease Subjects From Cognitively Normal Individuals","status":"COMPLETED","sponsor":"Avid Radiopharmaceuticals","startDate":"2009-03","conditions":"Alzheimer's Disease","enrollment":28},{"nctId":"NCT01565330","phase":"PHASE1","title":"A Study of Two Doses of 18F-AV-45 in Alzheimer's Disease and Healthy Volunteers","status":"COMPLETED","sponsor":"Avid Radiopharmaceuticals","startDate":"2008-03","conditions":"Alzheimer Disease","enrollment":20},{"nctId":"NCT01565356","phase":"NA","title":"Evaluation of PET Scan Timing Relative to AV-45 Injection Time","status":"COMPLETED","sponsor":"Avid Radiopharmaceuticals","startDate":"2010-03","conditions":"Alzheimer's Disease","enrollment":41},{"nctId":"NCT01565369","phase":"NA","title":"Evaluation of Physician Training Methods to Read Florbetapir-PET Scans","status":"COMPLETED","sponsor":"Avid Radiopharmaceuticals","startDate":"2011-01","conditions":"Alzheimer's Disease","enrollment":35},{"nctId":"NCT01550549","phase":"NA","title":"Evaluation of Web-based Training to Educate Physicians in the Methods of Interpreting Florbetapir-PET Scans","status":"COMPLETED","sponsor":"Avid Radiopharmaceuticals","startDate":"2011-08","conditions":"Alzheimer Disease, Mild Cognitive Impairment, Neurodegenerative Diseases","enrollment":151},{"nctId":"NCT00857415","phase":"PHASE3","title":"Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain","status":"COMPLETED","sponsor":"Avid Radiopharmaceuticals","startDate":"2008-12","conditions":"Alzheimer's Disease","enrollment":226},{"nctId":"NCT01564706","phase":"PHASE1","title":"A Study of 18F-AV-45 in Healthy Volunteers","status":"COMPLETED","sponsor":"Avid Radiopharmaceuticals","startDate":"2007-10","conditions":"Alzheimer Disease","enrollment":9},{"nctId":"NCT01565291","phase":"EARLY_PHASE1","title":"A Preliminary Study of 18F-AV-45 in Alzheimer's Disease and Healthy Elderly Volunteers","status":"COMPLETED","sponsor":"Avid Radiopharmaceuticals","startDate":"2007-06","conditions":"Alzheimer Disease","enrollment":32},{"nctId":"NCT01565343","phase":"PHASE1","title":"A Study of 18F-AV-45 in Alzheimer's Disease (AD) and Healthy Volunteers","status":"COMPLETED","sponsor":"Avid Radiopharmaceuticals","startDate":"2008-04","conditions":"Alzheimer's Disease","enrollment":25},{"nctId":"NCT00702143","phase":"PHASE2","title":"A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)","status":"COMPLETED","sponsor":"Avid Radiopharmaceuticals","startDate":"2008-06","conditions":"Alzheimer's Disease, Mild Cognitive Impairment","enrollment":184}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Florbetapir","Amyvid 18F-AV-45"],"phase":"marketed","status":"active","brandName":"Florbetapir F 18 (18F-AV-45)","genericName":"Florbetapir F 18 (18F-AV-45)","companyName":"University of California, San Francisco","companyId":"university-of-california-san-francisco","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Florbetapir F-18 is a positron emission tomography (PET) imaging agent that binds to amyloid-beta plaques in the brain to detect Alzheimer's disease pathology. Used for Detection of amyloid-beta pathology in patients with cognitive impairment or suspected Alzheimer's disease.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}